Genentech’s Polivy Gets US FDA Panel Nod For First-Line Use In Large B-Cell Lymphoma

Advisory committee members were swayed by a progression-free survival benefit, and the reduction in salvage therapies, with a polatuzumab-containing regimen relative to the highly effective standard of care in the POLARIX trial.